Clinical trials suggest that when the inflammation level is high initially (C-reactive protein >5 mg/dL), combined use of cytokine antagonists (e.g., TNF antagonist infliximab) and antidepressant therapy can improve the course of depression (Raison et al., 2013). This evidence concerns the gene CRP and depressive symptom measurement.